Trivalent intranasal influenza vaccine, live

被引:19
作者
McCarthy, MW
Kockler, DR
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA
[2] Virginia Commonwealth Univ, Med Ctr, Med Coll Virginia Hosp, Drug Informat Serv, Richmond, VA USA
关键词
FluMist; influenza vaccine; intranasal administration;
D O I
10.1345/aph.1E191
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To review human data on the efficacy, safety, and clinical use of trivalent intranasal influenza vaccine, live (TIIVL). Data Sources: A MEDLINE search (1966-3rd week of January 2004) using the terms influenza vaccine, intranasal administration, and FluMist was conducted. References from pertinent articles were also reviewed. Study Selection and Data Extraction: Studies conducted in humans and published in English were selected. Double-blind, controlled trials evaluating the efficacy and safety of TIIVL were evaluated. Data Synthesis: Administration of TIIVL results in mucosal and humoral immunity to influenza. Results of clinical trials in children and adults have demonstrated that TIIVL reduces the incidence of influenza. In children, TIIVL was also associated with a decrease in febrile illness and febrile otitis media. In adults, reductions in workday absences and medical visits due to febrile upper respiratory tract illness were also documented. TIIVL is well tolerated, with rhinorrhea or nasal congestion and sore throat occurring more frequently than with placebo. Conclusions: TIIVL is an alternative to intramuscular inactivated influenza vaccine in healthy individuals between 5 and 49 years of age. However, the vaccine is contraindicated in the majority of patient populations for whom annual influenza vaccination is recommended.
引用
收藏
页码:2086 / 2093
页数:8
相关论文
共 39 条
[1]  
Ali T, 2004, CLIN INFECT DIS, V38, P760, DOI 10.1086/382887
[2]   Prevention of otitis media in children with live attenuated influenza vaccine given intranasally [J].
Belshe, RB ;
Gruber, WC .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (05) :S66-S71
[3]   Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine [J].
Belshe, RB ;
Gruber, WC ;
Mendelman, PM ;
Mehta, HB ;
Mahmood, K ;
Reisinger, K ;
Treanor, J ;
Zangwill, Z ;
Hayden, FG ;
Bernstein, DI ;
Kotloff, K ;
King, J ;
Piedra, PA ;
Block, SL ;
Yan, LH ;
Wolff, M .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :1133-1137
[4]   Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine [J].
Belshe, RB ;
Gruber, WC ;
Mendelman, PM ;
Cho, I ;
Reisinger, K ;
Block, SL ;
Wittes, J ;
Iacuzio, D ;
Piedra, P ;
Treanor, J ;
King, J ;
Kotloff, K ;
Bernstein, DI ;
Hayden, FG ;
Zangwill, K ;
Yan, LH ;
Wolff, M .
JOURNAL OF PEDIATRICS, 2000, 136 (02) :168-175
[5]   The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [J].
Belshe, RB ;
Mendelman, PM ;
Treanor, J ;
King, J ;
Gruber, WC ;
Piedra, P ;
Bernstein, DI ;
Hayden, FG ;
Kotloff, K ;
Zangwill, K ;
Iacuzio, D ;
Wolff, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1405-1412
[6]   Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents [J].
Bergen, R ;
Black, S ;
Shinefield, H ;
Lewis, E ;
Ray, P ;
Hansen, J ;
Walker, R ;
Hessel, C ;
Cordova, J ;
Mendelman, PM .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (02) :138-144
[7]   Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children [J].
Bernstein, DI ;
Yan, LH ;
Treanor, J ;
Mendelman, PM ;
Belshe, R .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (01) :28-34
[8]   Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children [J].
Boyce, TG ;
Gruber, WC ;
Coleman-Dockery, SD ;
Sannella, EC ;
Reed, GW ;
Wolff, M ;
Wright, PF .
VACCINE, 1999, 18 (1-2) :82-88
[9]   Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine [J].
Bryant, ML ;
Brown, P ;
Gurevich, N ;
McDougall, IR .
NUCLEAR MEDICINE COMMUNICATIONS, 1999, 20 (02) :171-174
[10]  
*CDCP, VACC INF STAT VIS LI